Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Applied DNA Sciences, Inc. - Common Stock (NQ:APDN)

4.140 +1.230 (+42.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
Via ACCESSWIRE
Recap: Applied DNA Sciences Q1 Earnings
 
Via Benzinga
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q2 2024
APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We are starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to read about this morning! 
Via InvestorPlace
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Earnings Preview For Applied DNA Sciences
 
Via Benzinga
Applied DNA Sciences: Q4 Earnings Insights
 
Via Benzinga
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
Applied DNA Announces 1-For-20 Reverse Stock Split
Via ACCESSWIRE
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Via ACCESSWIRE
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Via ACCESSWIRE
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Via ACCESSWIRE
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023
APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.